Christiana Care https://christianacare.org has announced that the company has spun out its first commercial biotechnology private start-up company named CorriXR Therapeutics. https://www.corrixr.com.
The company will use CRISPER gene editing technology to develop new clinically relevant oncologic therapeutics in areas of unmet medical needs starting with squamous cell carcinoma of the lung.
Earlier this year, ChristianaCare’s Gene Editing Institute, now a wholly owned subsidiary, is positioned to advance research by using CRISPR gene editing technology to fast track discoveries for commercial applications.
The Gene Editing Institute, a leader in CRISPER gene editing technology and the only institute of its kind based within a community healthcare system takes a patient-first approach in all of the research to improve the lives of people with life-threatening diseases.
The new start-up company received $5 million in seed financing from Christiana Care and Brookhaven Bio. The start-up has developed unique CRISPR/Cas biomolecular tools that disable the genome of a tumor cell but not the genome of a healthy cell which enables target selectivity.
CorriXR Therapeutics will license technology from the Gene Editing Institute and work closely with scientific researchers and clinical oncologists at Christiana Care.